Literature DB >> 19079620

Cost-effectiveness of active versus conservative colposcopic management of mild dyskaryosis.

Mohsen M El-Sayed1, Wael I Al-Daraji, Chris M Finnegan, Wendy E Dugmore, Barbel U Vonau, Paul G Carter, Michael H Jones.   

Abstract

Management of mild dyskaryosis remains controversial. In this study, we compared the cost-effectiveness of active versus conservative colposcopic management of women presenting with mild dyskaryosis in two different hospital settings. All women presenting in 2001 with a mild dyskaryotic smear and requiring colposcopy were studied in two different clinical settings (70 women at Darent Valley Hospital (DVH) and 327 at St George's Hospital (SGH)). At DVH, treatment is offered should there be any evidence of cervical intraepithelial neoplasia (CIN). On the other hand, a more conservative approach of cytological and colposcopical follow-up is offered to patients with evidence of low-grade disease at SGH. The outcome of both groups of patients was determined in terms of the number of colposcopy visits per patient, the risk of missing disease as a consequence of patients lost to follow-up and hospital costs as well as costs to patient over a four-year period. The majority (70%) of DVH patients had 1-2 colposcopy visits whereas the majority (60%) of SGH patients had 3-7 visits. At SGH 44% of untreated patients were lost to follow-up and an unknown number of those might have had high-grade disease. Active management is more cost-effective compared with conservative management ( pound323 and pound589 as cost per patient effectively treated in the two hospitals respectively). In conclusion, active management of low-grade disease is associated with lower hospital and patient costs compared with the conservative strategy.

Entities:  

Keywords:  Mild dyskaryosis; colposcopy; cost-effectiveness; dysplasia; management

Year:  2008        PMID: 19079620      PMCID: PMC2600461     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  12 in total

1.  Spontaneous resolution rate of grade 1 cervical intraepithelial neoplasia in a private practice population.

Authors:  R K Falls
Journal:  Am J Obstet Gynecol       Date:  1999-08       Impact factor: 8.661

2.  Immediate colposcopy or cytological surveillance for women with mild dyskaryosis: a cost effectiveness analysis.

Authors:  G Flannelly; M K Campbell; P Meldrum; D J Torgerson; A Templeton; H C Kitchener
Journal:  J Public Health Med       Date:  1997-12

3.  Randomised trial of immediate versus deferred treatment strategies for the management of minor cervical cytological abnormalities.

Authors:  M I Shafi; D M Luesley; J A Jordan; J A Dunn; T P Rollason; M Yates
Journal:  Br J Obstet Gynaecol       Date:  1997-05

4.  The accuracy of repeat cytology in women with mildly dyskaryotic smears.

Authors:  J A Giles; A Deery; J Crow; P Walker
Journal:  Br J Obstet Gynaecol       Date:  1989-09

5.  A modified terminology for cervical intraepithelial neoplasia.

Authors:  R M Richart
Journal:  Obstet Gynecol       Date:  1990-01       Impact factor: 7.661

6.  The invasive potential of carcinoma in situ of the cervix.

Authors:  W A McIndoe; M R McLean; R W Jones; P R Mullins
Journal:  Obstet Gynecol       Date:  1984-10       Impact factor: 7.661

7.  Should patients with mild atypia in a cervical smear be referred for colposcopy?

Authors:  W P Soutter; S Wisdom; A K Brough; J M Monaghan
Journal:  Br J Obstet Gynaecol       Date:  1986-01

8.  Management of women with mild and moderate cervical dyskaryosis.

Authors:  G Flannelly; D Anderson; H C Kitchener; E M Mann; M Campbell; P Fisher; F Walker; A A Templeton
Journal:  BMJ       Date:  1994-05-28

9.  A prospective study of colposcopy in women with mild dyskaryosis or koilocytosis.

Authors:  B S Bolger; B V Lewis
Journal:  Br J Obstet Gynaecol       Date:  1988-11

10.  Psychological response to cervical screening.

Authors:  S Bell; M Porter; H Kitchener; C Fraser; P Fisher; E Mann
Journal:  Prev Med       Date:  1995-11       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.